Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults (Q24242809)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

review article

1 reference

title

Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

post-exposure prophylaxis

11 January 2020

main subject

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1

Kristine Macartney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

16 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

CD001833

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Antibody Response to Varicella-Zoster Virus after Natural or Vaccine-Induced Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccination of health-care workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella zoster virus: vaccination and implications in children with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunization of healthy adults with live attenuated varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

The risk of zoster after varicella vaccination in children with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Risk factors for breakthrough varicella in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Kinetics and Viral Protein Specificity of the Cytotoxic T Lymphocyte Response in Healthy Adults Immunized with Live Attenuated Varicella Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Live vaccine used to prevent the spread of varicella in children in hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Effectiveness over time of varicella vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella-zoster virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Postlicensure safety surveillance for varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella Vaccine in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Postmarketing evaluation of the safety and effectiveness of varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Vaccination to prevent varicella and shingles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Clinical practice. Herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Preventing varicella-zoster disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccination in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Outcome after maternal varicella infection in the first 20 weeks of pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

The postmarketing safety profile of varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccination--a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX? in healthy children*1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccination in children with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Immunogenicity and Safety of Measles-Mumps-Rubella, Varicella and Haemophilus influenzae Type b Vaccines Administered Concurrently With a Fourth Dose of Heptavalent Pneumococcal Conjugate Vaccine Compared With the Vaccines Administered Without Heptav

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Varicella vaccination in children with steroid-sensitive nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting--a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Live attenuated varicella vaccine: Immunization of healthy children with the OKA strain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Response to the varicella vaccine in children with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Administration of live varicella vaccine to children wtih leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immunisation of nurses with a live varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Live varicella vaccine in both immunocompromised and healthy children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

The varicella vaccine. Vaccine development

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immunization of HIV-infected children with varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Persistence of immunity to live attenuated varicella vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Enhancement of Varicella-Zoster-Specific Immune Responses in the Elderly by Boosting with Varicella Vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immune response of elderly individuals to a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Efficacy of high-titer live attenuated varicella vaccine in healthy young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Postexposure varicella vaccination in siblings of children with active varicella

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Varicella vaccination in HIV-1-infected children after immune reconstitution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Postexposure effectiveness of varicella vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

Clinical and Laboratory Studies of KMcC Strain Live Attenuated Varicella Virus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001833.PUB2

7 January 2021

10.1002/14651858.CD001833.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18646079%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference